205 related articles for article (PubMed ID: 32629594)
1. [Clinical features and outcomes in relapsing and monophasic patients with anti-leucine-rich glioma-inactivated 1 encephalitis].
Li JM; Ma XR; Peng T; Li JH; Lu H
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1947-1951. PubMed ID: 32629594
[No Abstract] [Full Text] [Related]
2. Clinical features of 28 cases of anti
Feng J; Li J; Xie Y; Lü Y; Bi F; Zhou J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):386-396. PubMed ID: 37164922
[TBL] [Abstract][Full Text] [Related]
3. CHI3L1 in the CSF is a potential biomarker for anti-leucine-rich glioma inactivated 1 encephalitis.
Li J; Li H; Wang Y; Zhao X; Wang S; Li L
Front Immunol; 2022; 13():1071219. PubMed ID: 36685530
[TBL] [Abstract][Full Text] [Related]
4. Clinical Features, Immunotherapy, and Outcomes of Anti-Leucine-Rich Glioma-Inactivated-1 Encephalitis.
Huang X; Fan C; Gao L; Li L; Ye J; Shen H
J Neuropsychiatry Clin Neurosci; 2022; 34(2):141-148. PubMed ID: 34794327
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and outcomes of leucine-rich glioma-inactivated protein 1 and contactin protein-like 2 antibody-associated autoimmune encephalitis in a Chinese cohort.
Li HY; Qiao S; Cui CS; Feng F; Liu XW; Yang XD
J Clin Neurosci; 2022 Jul; 101():137-143. PubMed ID: 35597061
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of anti-leucine-rich glioma-inactivated 1 encephalitis in northeast China.
Zhao Q; Sun L; Zhao D; Chen Y; Li M; Lu Y; Li G; Lin W
Clin Neurol Neurosurg; 2021 Apr; 203():106542. PubMed ID: 33706063
[TBL] [Abstract][Full Text] [Related]
7. Predicting the functional outcomes of anti-LGI1 encephalitis using a random forest model.
Li G; Liu X; Wang M; Yu T; Ren J; Wang Q
Acta Neurol Scand; 2022 Aug; 146(2):137-143. PubMed ID: 35373330
[TBL] [Abstract][Full Text] [Related]
8. Anti-LGI1 encephalitis recurring 3 years after the first episode: a case report.
Fujita H; Shioda M; Suzuki K
BMC Neurol; 2022 Apr; 22(1):148. PubMed ID: 35448972
[TBL] [Abstract][Full Text] [Related]
9. [Clinical analysis of 71 cases of anti-N-methyl-D-aspartate receptor encephalitis in children].
Wang GL; Yin F; Wang Y; Zhang WX; He F; Yang LF; Wu LW; Peng J
Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):125-130. PubMed ID: 30695887
[No Abstract] [Full Text] [Related]
10. Mycophenolate mofetil reduces the risk of relapse in anti-leucine-rich glioma-inactivated protein 1 encephalitis: a prospective observational cohort study.
Liu M; Xu X; Fan S; Ren H; Zhao Y; Guan H
Neurol Sci; 2024 Jan; 45(1):253-260. PubMed ID: 37580515
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study.
Celicanin M; Blaabjerg M; Maersk-Moller C; Beniczky S; Marner L; Thomsen C; Bach FW; Kondziella D; Andersen H; Somnier F; Illes Z; Pinborg LH
Eur J Neurol; 2017 Aug; 24(8):999-1005. PubMed ID: 28544133
[TBL] [Abstract][Full Text] [Related]
12. [Ictal electroencephalography (EEG) activity and cerebral blood flow dynamics as potential pathological indicators: a case of anti-leucine-rich glioma-inactivated 1 protein (LGI1) encephalitis].
Ishibashi H; Neshige S; Aoki S; Ueno H; Iida K; Maruyama H
Rinsho Shinkeigaku; 2020 Nov; 60(11):778-785. PubMed ID: 33115994
[TBL] [Abstract][Full Text] [Related]
13. Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2.
Murayama A; Sugaya K; Hara M; Kawazoe T; Tobisawa S; Nakajima H; Takahashi K
Intern Med; 2023 Jun; 62(11):1659-1663. PubMed ID: 36223927
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of 9 cases with Anti-leucine-rich glioma inactivated 1 protein antibody associated limbic encephalitis].
Zhang YX; Yang HL; Wu YY; Wang CC; Gao XY; Shi YY; Liu HQ; Huang Y; Zhang JW
Zhonghua Yi Xue Za Zhi; 2017 May; 97(17):1295-1298. PubMed ID: 28482428
[No Abstract] [Full Text] [Related]
15. What Is Different about Teratoma-Associated Anti-LGI1 Encephalitis? A Long-Term Clinical and Neuroimaging Case Series.
Li C; Cai HB; Zhao X; Xi XC; Zhou Q; Luo HY; Tang ZP; Kang HC; Kirsch HE
Eur Neurol; 2022; 85(6):437-445. PubMed ID: 35896086
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of patients with anti-leucine-rich glioma inactivated-1 protein associated encephalitis: a Chinese case series.
Yang X; Li AN; Zhao XH; Liu XW; Wang SJ
Int J Neurosci; 2019 Aug; 129(8):754-761. PubMed ID: 30621547
[No Abstract] [Full Text] [Related]
17. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study.
Li W; Wu S; Meng Q; Zhang X; Guo Y; Cong L; Cong S; Zheng D
BMC Neurol; 2018 Jul; 18(1):96. PubMed ID: 29980179
[TBL] [Abstract][Full Text] [Related]
18. Comparing clinical features, severity and prognosis of autoimmune encephalitis and with and without oligoclonal bands.
Xue H; Guo X; Jiang Y; Qin L; Wang X; Xu J; Zuo S; Liu Q; Li W
Front Neurol; 2023; 14():1281276. PubMed ID: 38249729
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis: a prospective cohort study in Western China.
Guo K; Liu X; Lin J; Gong X; Li A; Liu Y; Zhou D; Hong Z
Ther Adv Neurol Disord; 2022; 15():17562864211073203. PubMed ID: 35069805
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis.
Muñiz-Castrillo S; Haesebaert J; Thomas L; Vogrig A; Pinto AL; Picard G; Blanc C; Do LD; Joubert B; Berzero G; Psimaras D; Alentorn A; Rogemond V; Dubois V; Ambati A; Tamouza R; Mignot E; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33848259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
